<DOC>
	<DOCNO>NCT00653016</DOCNO>
	<brief_summary>The purpose study document experience transdermal contraceptive patch period 9 cycle , compare previous contraceptive method .</brief_summary>
	<brief_title>An Open-label , Multicentre Study Preference Satisfaction Canadian Women Transdermal Contraceptive Patch v . Previous Primary Contraceptive Method</brief_title>
	<detailed_description>This multicentre , single-arm , open-label study . The objective phase IV study document experience woman transdermal contraceptive patch ( weekly contraceptive patch deliver 150 mg norelgestromin/20 mg ethinyl estradiol daily ) period 9 cycle , compare previous contraceptive method . An open-label , multicentre , descriptive cohort study 392 woman require contraception enrol receive patch nine cycle . A single treatment cycle consist three consecutive 7-day patch application follow one patch-free week . At final visit , overall satisfaction preference patch rat compare previous contraceptive method . ) The primary outcome treatment preference overall satisfaction . Compliance , contraceptive efficacy , adhesion , safety measure secondary outcome . Study participant schedule receive contraceptive patch nine consecutive treatment cycle . Participants attend clinic 3 study visit : baseline/screening , Day 28 Cycle 3 Day 28 Cycle 9 ( early termination ) . A telephone interview conduct Day 28 Cycle 6 . Approximately 400 woman enrol study receive transdermal contraceptive patch . Patients recruit use ethic approve advertisement , addition investigator approach patient present routine well-woman check . Participants meet eligibility criterion instruct apply first patch first day next menses ( 13 week follow last medroxyprogesterone acetate injection ) wear patch seven day . They instruct apply new patch week 2 3 , patch-free week 4 . Applying new patch day week 4 end start new cycle . All patch applied/changed day week approximately time day . Only one patch worn time . Patches could apply buttock , abdomen , upper outer arm , upper torso ( exclude breast ) participant instruct apply new patch different site . Patches adhere ; supplemental tape adhesive permit . If patch partially detach , participant could reapply ; however , patch completely detach replace immediately replacement patch would wear remainder week . Eligible patient instruct apply 1st patch first day next menses ( 13 week follow last medroxyprogesterone acetate injection ) wear patch 7days . They instruct apply new patch week 2 3 , patch-free week 4 . Applying new patch day week 4 end start new cycle . All patch applied/changed day week approximately time day .</detailed_description>
	<mesh_term>Norelgestromin</mesh_term>
	<mesh_term>Norgestrel</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<criteria>Healthy female , sexually active risk pregnancy eligible participate study provide regular menses occur every 25 35 day ( except woman use medroxyprogesterone acetate ) woman use one follow method contraception primary method 3 month prior admission : oral contraceptive , intrauterine device , medroxyprogesterone acetate injection , doublebarrier method consist condom spermicidal foam gel , diaphragm spermicidal foam gel study participant normal Pap smear within previous 12 month negative urine pregnancy test admission systolic/diastolic blood pressure &lt; = 140/90 mm Hg within 35 % acceptable body mass index ( upper limit 32.4 ) willing switch current method contraception agree use steroid hormonal therapy topical corticosteroid inhale corticosteroid asthma , course study . History presence disorder commonly accept contraindication steroid hormonal therapy , e.g. , deep vein thrombophlebitis , thromboembolic disorder , cerebral vascular coronary artery disease , etc . Additionally , participant menopausal skin condition result oily , irritate damage skin potential application site Had history presence dermal hypersensitivity The presently use contraceptive method condom alone , abstinence , withdrawal , rhythm method Had receive medroxyprogesterone acetate injection &lt; =12 week prior enrolment history alcohol substance abuse within 12 month enrolment receive experimental drug device within 30 day enrolment Had use barbiturate , antiepileptic , rifampin , griseofulvin , hepatic enzyme induce drug within 30 day enrolment Chronic systemic antibiotic use Had uncontrolled thyroid disorder Were smoker age 35 Had Pap smear evidence atypical squamous cell adenocarcinoma malignancy Had desire conceive subsequent 9 month enrolment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Contraception</keyword>
	<keyword>norelgestromin</keyword>
	<keyword>ethinyl estradiol</keyword>
	<keyword>transdermal contraceptive patch</keyword>
	<keyword>EVRA</keyword>
	<keyword>ORTHO EVRA</keyword>
</DOC>